Camlin Fine Sciences

Date: 14/02/2018

To,	To,
BSE Limited, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	The Manager, Listing Department, **National Stock Exchange of India Ltd**., Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol: CAMLINFINE || Series: EQ

Sub: Outcome of the Board Meeting

The Board of Directors of the Company at its meeting held today i.e., 14th February, 2018, inter alia, has taken note and approved the Un-Audited Financial Results (standalone and consolidated) for the quarter ended 31st December, 2017. The un-audited results along with limited review reports are enclosed herewith as Annexure-1.

Kindly take the above information on records.

Encl.: a/a.

Thanking You,

For Camlin Fine Sciences Limited

Rahul D. Sawale
Group Company Secretary

CAMLIN FINE SCIENCES LIMITED MUMBAI

Registered Office:
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

PART I

(Rs.in Lakh, except per share data)

No.		PARTICULARS	STANDALONE					CONSOLIDATED				
			QUARTER ENDED			NINE MONTHS ENDED		QUARTER ENDED			NINE MONTHS ENDED	
			31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1		**Revenue from operations**										
		Sales / Income from operations	11,786.86	8,505.68	7,088.42	27,334.41	25,042.46	20,671.62	14,420.71	13,621.98	49,107.47	39,290.13
		Other income	323.43	554.73	1,044.70	399.08	1,219.73	211.52	422.65	905.13	287.79	1,340.56
		Total income	**12,110.29**	**9,060.41**	**8,133.12**	**27,733.49**	**26,262.19**	**20,883.14**	**14,843.36**	**14,527.11**	**49,395.26**	**40,630.69**
2		**Expenditure**										
		Cost of materials consumed	8,208.67	5,500.03	4,444.53	17,122.17	15,309.10	13,244.65	7,113.60	7,172.62	27,375.95	21,000.21
		Excise duty	-	-	228.11	214.24	1,038.53	-	-	228.11	215.76	1,038.53
		Purchase of stock in trade	844.08	368.29	589.00	1,381.86	1,468.70	19.28	357.10	79.30	557.06	959.00
		Changes in inventories of finished goods/WIP/stock in trade	715.56	577.46	(271.34)	2,636.06	(2,455.42)	(995.74)	128.20	(373.86)	1,175.60	(4,851.09)
		Employee benefits expense	518.96	433.26	531.83	1,403.14	1,532.25	1,850.94	1,684.34	1,627.66	5,147.41	4,419.50
		Finance costs	669.35	633.60	732.19	1,944.99	1,863.61	905.92	800.08	860.64	2,419.73	2,182.44
		Depreciation and amortisation expense	227.62	229.02	291.44	685.02	884.12	601.72	632.66	557.57	1,686.47	1,579.37
		Research and development expenses	56.12	44.51	59.25	147.66	204.55	56.12	44.51	59.25	147.66	204.55
		Other expenses	2,271.29	1,882.86	1,469.63	4,797.60	5,169.86	6,032.86	4,685.29	4,644.07	14,275.23	13,007.50
		Total Expenses	**13,511.65**	**9,669.03**	**8,074.64**	**30,332.74**	**25,015.30**	**21,715.75**	**15,445.78**	**14,855.36**	**53,000.87**	**39,540.01**
3		**Profit/(Loss) before share of profit of associate (1-2)**	**(1,401.36)**	**(608.62)**	**58.48**	**(2,599.25)**	**1,246.89**	**(832.61)**	**(602.42)**	**(328.25)**	**(3,605.61)**	**1,090.68**
4		**Share of profit / (loss) of associate**	-	-	-	-	-	-	**(2.15)**		**(1.68)**	-
5		**Profit / (Loss) before tax (3-4)**	**(1,401.36)**	**(608.62)**	**58.48**	**(2,599.25)**	**1,246.89**	**(832.61)**	**(604.57)**	**(328.25)**	**(3,607.29)**	**1,090.68**
6		**Tax Expenses**										
		- Current tax	-		28.59	-	380.08	183.19	193.96	244.74	689.75	1,140.96
		- Deferred tax	(583.28)	(241.84)	(3.77)	(1,059.28)	66.42	(513.98)	(460.08)	(228.14)	(2,325.70)	(75.18)
7		**Profit/(Loss) after tax (5-6)**	**(818.08)**	**(366.78)**	**33.66**	**(1,539.97)**	**800.39**	**(501.82)**	**(338.45)**	**(344.85)**	**(1,971.34)**	**24.90**
8		Other comprehensive income										
A	(i)	Items that will not be reclassified to profit or loss										
		Remeasurements of defined benefit plans	18.04	(13.16)	17.48	19.10	3.77	18.04	(13.16)	17.48	19.10	3.77
	(ii)	Income tax relating to Items that will not be reclassified to profit or loss	(5.97)	4.35	(5.78)	(6.32)	(1.25)	(5.97)	4.35	(5.78)	(6.32)	(1.25)
B	(i)	Items that will be reclassified to profit or loss										
		Exchange differences on translating the financial statements of subsidiaries	-		-	-	-	(391.06)	705.63	(551.23)	976.72	(887.81)
	(ii)	Income tax relating to Items that will not be reclassified to profit or loss	-		-	-	-	129.30	(233.30)	182.25	(322.93)	293.54
		Other comprehensive income	**12.07**	**(8.81)**	**11.70**	**12.78**	**2.52**	**(249.69)**	**463.52**	**(357.28)**	**666.57**	**(591.75)**
9		**Total comprehensive income for the period (7+8)**	**(806.01)**	**(375.59)**	**45.36**	**(1,527.19)**	**802.91**	**(751.51)**	**125.07**	**(702.13)**	**(1,304.77)**	**(566.85)**
10		**Profit / (loss) attributable to:**			-							
	(i)	Owners of the Company	(818.08)	(366.78)	33.66	(1,539.97)	800.39	(1,031.91)	(414.77)	(471.52)	(2,654.39)	(411.86)
	(ii)	Non-controlling interests	-	-		-	-	530.09	76.32	126.67	683.05	436.76
11		**Other comprehensive income attributable to:**										
	(i)	Owners of the Company	12.07	(8.81)	11.70	12.78	2.52	(149.06)	446.75	(373.21)	707.14	(544.33)
	(ii)	Non-controlling interests	-	-	-	-	-	(100.63)	16.77	15.93	(40.57)	(47.42)
12		**Total comprehensive income attributable to:**										
	(i)	Owners of the Company	(806.01)	(375.59)	45.36	(1,527.19)	802.91	(1,180.97)	31.98	(844.73)	(1,947.25)	(956.19)
	(ii)	Non-controlling interests	-	-		-	-	429.46	93.09	142.60	642.48	389.34
13		Paid-up Equity Share Capital (Face Value Re.1/- per share)	1,211.55	1,037.86	1,032.59	1,211.55	1,032.59	1,211.55	1,037.86	1,032.59	1,211.55	1,032.59
14		Earnings per Share (EPS) (of Re.1/-each) (not										
		Basic (Rs.)	(1.16)	(0.35)	0.03	(1.84)	0.64	(1.36)	(0.40)	(0.47)	(2.89)	(0.57)
		Diluted (Rs.)	(1.16)	(0.35)	0.03	(1.84)	0.63	(1.36)	(0.40)	(0.47)	(2.89)	(0.56)

CAMLIN FINE SCIENCES LTD. MUMBAI

KALYANIWALLA & MISTRY LLP MUMBAI

Notes to financial results:

1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 14, 2018. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016. The above results have been subjected to a limited review by the Statutory Auditors of the company.

2 The statement does not include Ind AS compliant results for the preceding quarter and previous year ended March 31, 2017 as the same are not mandatory as per SEBI's circular dated July 5, 2016.

3 Sales for the quarter and six months ended December 31, 2017 is net of Goods and Service Tax, GST , however the sales till the period ended June 30, 2017 and other comparative periods are gross of excise duty. The net revenue from operations (net of GST / excise duty) as applicable are stated below:

Particulars	STANDALONE					CONSOLIDATED				
	QUARTER ENDED			NINE MONTHS ENDED		QUARTER ENDED			NINE MONTHS ENDED	
	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016	31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Net revenue from operations	11,609.46	8,620.74	6,757.08	26,941.82	23,670.32	20,313.10	14,550.72	13,201.58	48,471.46	37,828.91

4 The reconciliation of net profit for the quarter and nine months ended December 31, 2016 reported as per Indian GAAP to profit as per Ind AS is as under:

Particulars	Standalone		Consolidated	
	Quarter	Nine Months	Quarter	Nine Months
Profit / (Loss) after tax as per Indian GAAP	10.15	764.69	(493.04)	(442.23)
Impact of fair valuation of security deposits (net)	(0.03)	(0.21)	(0.03)	(0.21)
Impact of fair valuation of mutual funds	31.24	63.53	31.24	63.53
Impact of fair valuation of corporate guarantee	1.96	5.34	-	
Actuarial gain on employee defined benefit plan recognised in other comprehensive income	1.17	3.50	1.17	3.50
Capitalisation of borrowing costs	5.72	13.31	5.72	13.31
Loss on measurement of employee stock options at fair value	(16.57)	(49.72)	(16.57)	(49.72)
Deferred tax impact of above adjustments	0.02	(0.05)	(0.01)	(0.04)
Profit / (Loss) after tax as per Ind AS	**33.66**	**800.39**	**(471.52)**	**(411.86)**

5 On July 12, 2017, CFS Europe S.p.A. along with the Company has completed the process of acquisition of 51% equity stake in CFS Wanglong Flavors (Ningbo) Co.Ltd., China for a total consideration of US$ 6.28 mln. Pursuant to this acquisition, CFS Wanglong Flavors (Ningbo) Co. Ltd. has become a step down subsidiary of the Company.

6 Maharashtra Pollution Control Board (MPCB) had issued a closure notice to manufacturing unit at Tarapur on 25th April, 2017 for violation of pollution control norms. After due representation, MPCB has issued a restart notice on 16th May, 2017 and the unit has restarted its operations. Management do not foresee any adverse impact on the financial results of the Company.

7 Out of the net proceeds of Rs.5,408.49 lakh pursuant to QIP Issue on July 5, 2016, the Company has utilized the proceeds as per the object of the issue being, meeting of expenses and investments pertaining to expansion and diversification of the business as follows:

Particulars	(Rs. In Lakh)
Capital expenditure including capital advances	661.96
Investments in subsidiaries	2,101.29
Loans to subsidiaries (including advances of Rs.702.40 lakh)	1,969.13
Foreign consultant fees	314.22
General corporate purposes	361.89
Total	**5,408.49**

KALYANIWALLA & MISTRY LLP MUMBAI

CAMLIN FINE SCIENCES LTD. MUMBAI

Registered Office:
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

8 On November 23, 2017, the Company has allotted 17,241,379 equity shares of Re. 1 each at a premium of Rs. 86 per share amounting to share proceeds of Rs. 15,000 lakh pursuant to a Qualified Institutions Placement (QIP) under Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009. Share issue expenses amounting to Rs.412.83 lakh has been adjusted against Securities Premium Account in terms of Section 52 of the Companies Act, 2013.

9 Out of the net proceeds of Rs.14,587.17 lakh, the Company has utilized the proceeds as per the object of the issue as follows:

Particulars	(Rs. In Lakh)
Capital expenditure	429.29
Loans to subsidiaries	666.05
General corporate purposes	334.49
Total	**1,429.83**

Pending utilization, the balance amount of the net proceeds of Rs. 13,235.30 are invested in mutual funds.

10 At the EOGM held on December 26, 2017, the shareholders have approved an issue of 90,00,000 warrants at a price of INR 92.69 each on a preferential basis to certain proposed allottees aggregating to INR 83.42 crores. 25% of the price was to be subscribed initially and the balance 75% of the consideration shall be paid at the time of allotment of equity shares pursuant to exercise of option against each such warrant by the proposed allottees. Each warrant will be converted into 1 equity share at the face value of INR 1 and share premium of INR 91.69 on or before the end of 18 months from the date of allotment of warrants. Accordingly, the initial 25% of the warrant price amounting to INR 20.86 crores was received on February 08, 2018 and accordingly warrants were issued to the proposed allottees on February 09, 2018.

11 On October 12, 2017 and December 12, 2017, the Company has issued and allotted 52,500 and 75,337 equity shares of Re.1 each respectively at a premium of Rs. 66 per equity share aggregating to Rs. 85.65 lakh under Employees Stock Option Scheme. During the quarter, 87,350 options have lapsed.

12 Other expenses include foreign exchange fluctuation loss amounting to Rs. 564.08 lakh and Rs. 98.35 lakh respectively for quarter ended & nine months ended 31.12.2017 on standalone basis and Rs. 409.75 lakh and Rs. 133.23 lakh respectively for quarter ended and nine months ened 31.12.2017 on consolidated basis.

13 The Company has invested Rs. 56.01 lakh in the share capital of Solentus North America Inc., its wholly owned subsidiary Company ('the subsidiary") and given a loan of Rs. 205.42 lakh to it upto December 31, 2017. The subsidiary has negative net worth as at December 31, 2017 and is dependent upon the Company to enable it to meet its obligations as they become due. Based on the proposed plans for the subsidiary, management believes the loan to be fully recoverable and further believes that there is no diminution other than temporary in its investment in the share capital of the subsidiary.

14 Consolidated Gross sales/Income from operation is net of Sales/Purchase between company and its subsidiary companies.

15 During the period, CFS Europe SpA, Italy, carried out routine maintenance and upgradation of its manufacturing facility.

16 On May 4, 2016,CFS Antioxidantes De Mexico S.A.de C.V. Mexico, wholly owned subsidiary of the company had acquired 65% equity stake in Dresen Quimica S.A.P.I.de C.V., Mexico and its subsidiaries. Results of these subsidiaries have been consolidated for the entire current period, while for the period May 4, 2016 to December 31, 2016 in corresponding quarter of earlier year. On July 12, 2017, the Company had acquired 51% equity stake in Ningbo Wanglong Flavors & Fragrances, China. Results of this subsidiary has been consolidated for the current period. Hence the corresponding figures of quarter and nine months ended December 16 are not comparable.

17 The Company's operations constitute a single business segment business in Fine Chemicals.

18 Figures for previous periods have been regrouped/rearranged wherever necessary.

FOR CAMLIN FINE SCIENCES LIMITED

Ashish S. Dandekar
Managing Director

Place: Mumbai
Date: February 14, 2018

KALYANIWALLA & MISTRY LLP MUMBAI

CAMLIN FINE SCIENCES LTD. MUMBAI

CFS Camlin Fine Sciences

Limited Review Report on Quarterly and Nine months unaudited Standalone Financial Results of Camlin Fine Sciences Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors
Camlin Fine Sciences Limited
F/11-12, WICEL, Opposite SEEPZ,
Central Road, Andheri (East),
Mumbai - 400093

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results ("the statement") of Camlin Fine Sciences Limited for the quarter and nine months ended December 31, 2017, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors at its meeting held on February 14, 2018. Our responsibility is to issue a report on these Unaudited Standalone financial results based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. The Financial results for the quarter and nine months ended December 31, 2016, included in the Statement, are based on the previously issued financial results of the Company, prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 ('previous GAAP'), which were reviewed by M/s. B. K. Khare & Co. Chartered Accountants, whose report dated February 10, 2017 expressed an unmodified opinion on those unaudited standalone financial results. Management has adjusted these results for the differences in the accounting principles adopted by the Company on transition to the Indian Accounting Standards ('Ind AS') and presented a reconciliation of profit under Ind AS of the corresponding quarter and nine months with the profit reported under previous GAAP, which have been approved by the Company's Board of Directors and reviewed by us.

KALYANIWALLA & MISTRY LLP
MUMBAI

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Standalone Financial Results prepared in accordance with the applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5. We draw attention to Note 13 to the Notes to financial results relating to an investment made by the Company in the share capital of Solentus North America Inc., its wholly owned subsidiary company amounting to Rs. 56.01 Lakhs and to whom it has also advanced a loan aggregating to Rs. 205.42 Lakhs. The subsidiary has negative net worth as at December 31, 2017 and is dependent upon the Company to enable it to meet its obligations as they become due. In the opinion of the management, the fall in value of the equity shares is temporary and the recoverability of the above loan is dependent on successful implementation of management's future plans in respect of the said subsidiary.

   Our opinion is not modified in respect of the above matter.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166

FARHAD M. BHESANIA
PARTNER
Membership Number 127355
Place: Mumbai
Date: February 14, 2018

Limited Review Report on Quarterly and Nine months unaudited Consolidated Financial Results of Camlin Fine Sciences Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

The Board of Directors
Camlin Fine Sciences Limited
F/11-12, WICEL, Opposite SEEPZ,
Central Road, Andheri (East),
Mumbai - 400093

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results ("the statement") of Camlin Fine Sciences Limited ('the Company') and its subsidiaries (the Company and its subsidiaries together referred to as the group) and its associate for the quarter and nine months period ended December 31, 2017, prepared by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors at its meeting held on February 14, 2018. Our responsibility is to issue a report on these unaudited consolidated financial results based on our review.

2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. The Financial results for the quarter and nine months ended December 31, 2017, included in the Statement, are based on the previously issued financial results of the Company, prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 ('previous GAAP'), which were reviewed by M/s. B. K. Khare & Co. Chartered Accountants, whose report dated February 10, 2017 expressed an unmodified opinion on those unaudited consolidated financial results. Management has adjusted these results for the differences in the accounting principles adopted by the Company on transition to the Indian Accounting Standards ('Ind AS') and presented a reconciliation of profit under Ind AS of the corresponding quarter and nine months with the profit reported under previous GAAP, which have been approved by the Company's Board of Directors and reviewed by us.

KALYANIWALLA & MISTRY LLP
MUMBAI

4. We did not review the financial results of ten subsidiaries incorporated outside India and a subsidiary in India, whose interim financial results reflect total revenue of Rs. 15,342.13 Lakhs and Rs. 37,314.79 Lakh for the quarter and nine months ended December 31, 2017, as considered in the consolidated financial results. These financial statements have been reviewed by other auditors whose report has been furnished to us by the Management and our opinion on the quarterly consolidated financial results, to the extent they have been derived from such financial statements is based solely on the report of such other auditors.

   In case of subsidiaries located outside India, interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the interim financial results of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards 'Ind AS'). We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the amounts and disclosures of such subsidiaries located outside India is based on the report of the other auditors and the conversion adjustments made by the management of the Company and reviewed by us. Our opinion is not modified in respect of this matter.

5. The financial result of four subsidiaries, whose financial result reflects the Group's share of total revenue of Rs. 500.07 Lakhs and Rs. 1,278.65 Lakhs for the quarter and nine months ended December 31, 2017 respectively as considered in Consolidated Financial Results, are not reviewed as of the date of this report and have been included in the Consolidated Financial Results on the basis of Unaudited Management Accounts. The consolidated financial results also include the Group's share of net loss of Rs. 1.68 Lakhs in respect of an associate whose financial statements has not been reviewed by us. Our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on such unaudited financial information. Our conclusion is not modified in respect of this matter.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Consolidated Financial Results prepared in accordance with the applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS
Firm Registration Number 104607W/W100166

FARHAD M. BHESANIA
PARTNER
Membership Number 127355
Place: Mumbai
Dated: February 14, 2018

Camlin Fine Sciences

	Extract of Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2017			
		QUARTER ENDED		NINE MONTHS ENDED
		31.12.2017	31.12.2016	31.12.2017
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total Income from Operations	20,671.62	13,621.98	49,107.47
2	Net Profit/(Loss) from ordinary activities after tax	(501.82)	(344.85)	(1,971.34)
3	Net Profit/(Loss) for the period after tax and non-controlling interests (after extraordinary items)	(1,031.91)	(471.52)	(2,654.39)
4	Total Comprehensive Income for the period	(751.51)	(702.13)	(1,304.77)
5	Equity Share Capital	1,211.55	1,032.59	1,211.55
6	Earnings per share (before and after extraordinary items) (of Re 1/- each)			
	-Basic Rs.	(1.36)	(0.47)	(2.89)
	-Diluted Rs.	(1.36)	(0.47)	(2.89)

1 The above information is an extract of the detailed format of unaudited results for the quarter and nine months ended December 31, 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter ended December 31, 2017 are available on the Company's website,www.camlinfs.com and the Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com.

2 The reconciliation of consolidated net profit for quarter and nine months ended December 31, 2016 reported as per Indian GAAP to profit as per Ind AS as under:

Particulars	Quarter	Nine Months
Profit / (Loss) after tax as per Indian GAAP	(493.04)	(442.23)
Impact of fair valuation of security deposits (net)	(0.03)	(0.21)
Impact of fair valuation of mutual funds	31.24	63.53
Actuarial gain on employee defined benefit plan recognised in other comprehensive income	1.17	3.50
Capitalisation of borrowing costs	5.72	13.31
Loss on measurement of employee stock options at fair value	(16.57)	(49.72)
Deferred tax impact of above adjustments	(0.01)	(0.04)
Profit / (Loss) after tax as per Ind AS	**(471.52)**	**(411.86)**

FOR CAMLIN FINE SCIENCES LIMITED

CAMLIN FINE SCIENCES LTD. MUMBAI

Ashish S. Dandekar
Managing Director

Place: Mumbai
Date: February 14, 2018

Registered Office:
Camlin Fine Sciences Ltd. F/11-12, WICEL, Opp. SEEPZ, Central Road, Andheri East, Mumbai 400093, India.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com